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Summary
Sub-Saharan Africa (“Africa” hereafter) has been more severely affected by
AIDS than any other part of the world.  In 2005, the United Nations reports, there
were in the range of 24.5 million HIV-positive persons in the region, which has just
over 11% of the world’s population but about 64% of the worldwide total of infected
persons.  The overall adult rate of infection in Africa in late 2005 was 6.1%,
compared with 1% worldwide. Nine southern African countries have infection rates
above 10%.  Ten African countries with the largest infected populations account for
over 50% of infected adults worldwide.  By the end of 2005, an estimated 27.1
million or more Africans had died of AIDS since 1982, including 2 million in 2005.
AIDS has surpassed malaria as the leading cause of death in Africa, and it kills many
times more Africans than war.  In Africa, about 59% of infected adults are women.
Experts attribute the severity of Africa’s AIDS epidemic to the region’s poverty,
women’s relative lack of empowerment, high rates of male worker migration, and
other factors.  Health systems are ill-equipped for prevention, diagnosis, and
treatment.  AIDS’ severe social and economic consequences are depriving Africa of
skilled workers and teachers, and reducing life expectancy by decades in some
countries.  There are an estimated 12.3 million African AIDS orphans.  They face
increased risk of malnutrition and reduced prospects for education.  AIDS is blamed
for declines in farm production in some countries and is seen as a major contributor
to hunger and famine.
Donor governments, non-governmental organizations, and African governments
have responded by supporting programs aimed at preventing and reducing the
number of new infections and by trying to abate damage done by AIDS to families,
societies, and economies.  The adequacy of this response is the subject of much
debate.  An estimated 810,000 Africa AIDS patients were being treated with
antiretroviral drugs in late-2005, up from 150,000 in mid-2004.  An estimated total
of 4.7 million persons were in need of such therapy.  U.S. and other initiatives are
expected to sharply expand access to treatment in the near future. Advocates see this
goal as an affordable means of reducing the impact of the pandemic.  Skeptics
question whether drugs can be made widely accessible without costly health
infrastructure improvements.
U.S. concern over AIDS in Africa grew in the 1980s, as the epidemic’s severity
became apparent.  Legislation enacted in the 106th and the 107th Congresses increased
funding for worldwide AIDS programs.  P.L. 108-25, signed into law on May 27,
2003, authorized $15 billion over five years for international AIDS programs.
President Bush announced his Emergency Plan for AIDS Relief (PEPFAR) in his
2003 State of the Union message.  Twelve of 15 PEPFAR “focus countries” are in
Africa.  Under the FY2007 budget request, the 12 countries would receive a 61%
boost in AIDS-related aid, to $1.99 billion, under the State Department’s Global
HIV/AIDS Initiative account.  Nonetheless, activists and others urge that more be
done, given the scale of the African pandemic.  This CRS report replaces CRS Issue
Brief IB10050, AIDS in Africa, by Nicolas Cook.  It will be updated as circumstances
warrant.
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The Group of Eight (G8) member states, meeting at their 2006 summit in
Russia, took note of their shared support for and participation in passing the Political
Declaration on HIV/AIDS (A/RES/60/262), adopted at the 2006 U.N.  High-level
Meeting on AIDS.  The G8 also made a commitment to help secure funding and
support for the Global Fund to Fight AIDS, Tuberculosis and Malaria during its
2006-2007 replenishment period. Members did not make any joint new Africa-
specific commitments to fight AIDS.1  The U.N. High-level Meeting, which was held
from May 31 to June 2, 2006, received a Joint United Nations (U.N.) Program on
HIV/AIDS (UNAIDS)-coordinated update on the epidemic, entitled the 2006 Report
on the Global AIDS Epidemic.  Released on May 30, the report describes and
provides current data on the worldwide impact of AIDS on people and societies, the
status of prevention, treatment, and care, and other issues concerning national and
international response to AIDS, including in Africa.2 
High-level Meeting participants reviewed  progress made in countering AIDS
since the passage by the U.N. General Assembly Special Session on AIDS
(UNGASS) in 2001 of the Declaration of Commitment on HIV/AIDS
(A/RES/S-26/2).  They also considered recommendations to achieve AIDS treatment,
care and other targets, and renewed diverse global political commitments to counter
AIDS, as reflected in their passage of the Political Declaration on HIV/AIDS.  It
reaffirms their commitment to fully implement their 2001 declaration and to scale up
activities and the provision of financial and other resources necessary to ensure
universal international access to comprehensive HIV prevention, treatment, care and
support programs by 2010.3 
In April 2006, the Government Accountability Office (GAO) issued a report
entitled Global Health: Spending Requirement Presents Challenges for Allocating
Prevention Funding under the President’s Emergency Plan for AIDS Relief.4  The
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GAO found that PEPFAR guidance requiring certain amounts of spending on
abstinence and faithfulness-focused programs had, in some cases, led to decreases in
funding for other types of HIV prevention efforts, and suggested that certain program
implementation guidelines may have lacked clarity.
Release of the GAO report followed the State Department’s release in February
2006 of the second annual President’s Emergency Plan for AIDS Relief (PEPFAR)
report to Congress. It highlighted increases in diverse U.S.-backed HIV prevention
and care efforts, support for increased antiretroviral drug treatment, and a continuing
rise in U.S. international AIDS spending.  It also spotlighted  the PEPFAR New
Partners Initiative, launched by the President on World AIDS Day in December 2005.
The Initiative seeks to identify and provide U.S. competitive grant support to “new
partners,” including faith-based and community health care providers that are active
in the developing world but lack experience working with the U.S. government.  Also
in February, the Global Partners Forum, a group of public and private sector
organizations and governments met to seek ways to enhance global commitments for
HIV-affected children in areas such as protection, prevention, treatment, and care
capacities globally.  The Global Steering Committee, a new international effort to
provide universal AIDS treatment access by 2010, was launched in Washington in
January 2006.  It seeks to overcome key challenges to global anti-AIDS program
effectiveness, such as lack of sustainable financing, health care system constraints,
lack of development of and access to low-cost drugs and tests, and AIDS-related
social stigma. 
The Assistance for Orphans and Other Vulnerable Children in Developing
Countries Act of 2005 (P.L. 109-95; see section on Orphans, below), was signed into
law in November 2005. At a September 2005 London conference, the United States
pledged $600 million of $3.7 billion in total pledges by governments to the Global
Fund in 2006 and 2007.  This amount would fund renewals of existing Global Fund
grants but not new ones. International AIDS issues are further covered in CRS Report
RL33485, U.S. International HIV/AIDS, Tuberculosis, and Malaria Spending:
FY2004-FY2007, CRS Report RL33396, The Global Fund to Fight AIDS,
Tuberculosis, and Malaria: Progress Report and Issues for Congress, by  and CRS
Report RL31712, The Global Fund to Fight AIDS, Tuberculosis, and Malaria:
Background, all three written by Tiaji Salaam-Blyther.
Background
Sub-Saharan Africa (“Africa” hereafter) has been far more severely affected by
AIDS than any other world region.  In May 2006, UNAIDS reported that in 2005,
there were between 21.66 million and 27.40 million HIV-positive adults and children
in Africa, including 2.7 million newly infected during the year.  Africa has just over
11% of the world’s population but about 64% of the global HIV-positive population.
The infection rate among adults averaged an estimated 6.1% in Africa in 2005,
compared with about 1% worldwide. About 2 million adults and children were
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aggregating the total numbers of deaths reported for all years since 1982, based on data
reported in various published UNAIDS and World Health Organization (WHO) sources (list
available from the author). This method may not be statistically or methodologically sound,
in part because statistical and data collection methods have changed over time or varied
from study to study, and because many statisticians harbor doubts about the reliability of
death and infection rate data collected during the early years of the epidemic. UNAIDS does
not regularly publish aggregate historical regional mortality figures for Africa for similar
reasons, and because not all countries have authorized the release of data covering all years.
6 The following data are primarily drawn from UNAIDS, 2006 Report on the Global AIDS
Epidemic, supplemented by other UNAIDS and other U.N. agency source data.
estimated to have died of AIDS in 2005. Based on aggregate estimates of deaths
caused by AIDS, between 27.1 million and 27.7 million Africans have died of AIDS
since 1982 at the start of the epidemic,5 including about 2 million in 2005.  UNAIDS
has projected that between 2000 and 2020, 55 million Africans will likely have lost
their lives to AIDS, which causes more deaths than malaria in African adults, and
kills many times more people than Africa’s armed conflicts. 
Table 1.  African Adult HIV Infection Rates (%), End of 2005
More Than 10% 5% - 10% <0.1% - 5%
Swaziland 33.4 Gabon 7.9 Nigeria 3.9 Burkina Faso 2
Botswana 24.1 Côte d’Ivoire 7.1 Guinea-Bissau 3.8 Benin 1.8
Lesotho 23.2 Uganda 6.7 Angola 3.7 Mali 1.7
Zimbabwe 20.1 Tanzania 6.5 Chad 3.5 Sierra Leone 1.6
Namibia 19.6 Kenya 6.1 Burundi 3.3 Sudan 1.6
South Africa 18.8 Cameroon 5.4 Congo, Dem. Rep. 3.2 Guinea 1.5
Zambia 17 Congo 5.3 Equat. Guinea 3.2 Niger 1.1
Mozambique 16.1 Togo 3.2 Senegal 0.9
Malawi 14.1 Djibouti 3.1 Somalia 0.9
Cent. African Rep. 10.7 Rwanda 3.1 Mauritania 0.7
Eritrea 2.4 Mauritius 0.6
Gambia 2.4 Madagascar 0.5
Ghana 2.3 Comoros <0.1
Source: UNAIDS, 2006 Report on the Global AIDS Epidemic. No prevalence rates were reported for Cape Verde
or Sao Tome. Preliminary data for Ethiopia of between 0.9% and 3.5% were reported. Data for Liberia of
between 2% and 5% were reported; estimates from other sources range as high as 12%. UNAIDS is a key source
of national AIDS data in Africa. Its data are widely seen as accurately reflecting trends, though some researchers
assert that improved data collection and statistical models are showing that it may have overestimated infection
rates in some countries.  See Craig Timberg, “How AIDS in Africa was Overstated,” Washington Post, Apr. 6,
2006.
Characteristics of the African Epidemic6
Transmission.  In Africa according to most experts, HIV — the human
immunodeficiency virus that causes AIDS — is spread primarily by heterosexual
contact, though  some believe that the role of unsafe medical practices in the spread
of HIV may have been underestimated. Medical HIV transmission prevention is a
component of the President’s Emergency Plan for AIDS Relief (PEPFAR).
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8 UNAIDS/UNICEF/U.S. Agency for International Development, Children on the Brink,
July 2004. Estimates vary. Some earlier estimates had put the number as high as 12.3
million. In November 2003, UNICEF predicted that 20 million children would be orphaned
(continued...)
Women. According to UNAIDS, there were about 13.2 million HIV-positive
women in Africa in 2005. They comprised about 59% of infected adults in Africa and
about 76% of HIV-positive females globally. Young women are notably at risk. In
2005, about 4.3% of African women aged 15 to 24 were HIV-positive, compared
with 1.5% of young men.  These figures had dropped from 6.9% and 2.2%,
respectively, in 2004.
Prevalence Trends.  UNAIDS has reported that Africa’s adult HIV infection
rate, or prevalence, has stabilized in recent years, having peaked in the late 1990s, as
both the total adult and infected populations have increased.  Stabilization means that
numbers dying approximate the numbers of newly infected.  HIV has become
endemic in many countries and at a minimum will affect several future generations.
There have been declines in Kenya, Zimbabwe, and urban areas in some countries,
but prevalence is increasing in southern Africa (apart from Zimbabwe and Angola);
remains unchanged or slightly declining in West and Central Africa, where overall
rates are lower than in other regions of Africa; and is level or decreasing in several
East and Horn of Africa countries, though there is much local variation.
Highest Rates.  Southern Africa, where nine countries have adult infection
rates above 10% (Table 1), is the most severely affected region. With about 1.65%
of the world’s population in 2005, based on U.S. Census estimates, these countries
account for about 31.2% of infected people worldwide and 49% of those in Africa.
However, populous Nigeria in West Africa, with an estimated 3.9% adult infection
rate, has an estimated 2.9 million infected people,7 the largest number in Africa apart
from South Africa, where between 5.5 million and 6.1 million [UNAIDS average and
South African government estimates] are infected — the largest such population in
the world. 
Children.  Africa’s AIDS epidemic has a proportionally much greater effect
on children in Africa than in other world regions.  According to UNAIDS, over
600,000 African infants become infected yearly with HIV through mother-to-child
transmission, either at birth or through breast-feeding.  Most die before the age of
two.  Nonetheless, an estimated 2 million African children under age 15 were living
with AIDS in late 2005. Nearly 90% of HIV-positive children worldwide live in
Africa.  Less than 10% of these African children receive basic support services.  An
estimated 12 million children less than 17 years of age, slightly less than 10% of all
African children, have lost one or both parents to AIDS.
Orphans.  By late 2005, according to UNAIDS estimates published in 2006,
there were about 12 million AIDS orphans (children 17 and under who had lost one
or both parents to HIV) in Africa, up from about 10.2 million in late 2003, when
AIDS orphans comprised in the range of 28% of all orphans in the region.   By 2010,
their number is forecast to rise to 18.4 million, or 36.8% of all orphans.8 Because of
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by AIDS by 2010 and that in a dozen countries orphans from all causes would make up 15%
to over 25% of children under 15; see Africa’s Orphaned Generations.
AIDS-related social stigma, HIV-positive orphans are at high risk for
malnourishment, abuse, and denial of education. UNICEF has recommended that the
capacity of families and communities to protect and care for orphans be strengthened,
that social and state protection services be provided for orphans and vulnerable
children (OVCs), and that public education about HIV-affected children (including
HIV-infected children and those who may suffer indirect effects of AIDS, e.g., those
who come from families  with HIV-positive members) be increased.  In October
2005, Human Rights Watch alleged in a report that African governments have largely
not addressed the myriad barriers to education faced by AIDS-affected OVCs. P.L.
108-25 included sense of Congress language recommending that 10% of U.S.
HIV/AIDS international assistance should fund orphans and vulnerable children.
As previously noted, the Assistance for Orphans and Other Vulnerable Children
in Developing Countries Act of 2005 (P.L. 109-95) became law in November 2005.
It authorizes U.S. assistance for basic care for orphans and vulnerable children in
developing countries, including aid for community-based care, school food programs,
education and employment training, psycho-social support, protection of inheritance
rights, and AIDS care.
Explaining the African Epidemic
AIDS experts attribute Africa’s AIDS epidemic to a variety of economic and
social factors, but place primary blame on the region’s poverty, which has deprived
Africa of effective systems of health information, health education, and health care.
As a result, Africans suffer from high rates of untreated sexually-transmitted
infections other than AIDS, increasing their susceptibility to HIV.  African health
systems often have limited capabilities for AIDS prevention work, and HIV
counseling and testing are difficult for many Africans to obtain.  Until very recently,
AIDS treatment was generally available only to elites.
Poverty forces large numbers of African men to migrate long distances in search
of work, and while away from home they may have multiple sex partners, increasing
their risk of infection.  Some of these partners may be women who engage in
commercial or “transactional” sex because of poverty, which makes them highly
vulnerable to infection.  Migrant workers may carry the infection back to their wives
when they return home.  Long-distance truck and public transport drivers are also
seen as key agents in the spread of HIV. 
Women and girls are disproportionately affected by AIDS in Africa. According
to UNAIDS officials and publications, among other sources, contraction of HIV by
girls from older men is a significant factor contributing to higher rates of infection
among young women than in young men.  While older men are more likely than
young men to be HIV-positive, girls in impoverished contexts often view
relationships with older men as vital opportunities for achieving financial, material,
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and social security.  According to surveys, in many African countries, large numbers
of young women lack comprehensive knowledge of HIV transmission. 
Many believe that female infection rates would be lower if women’s rights were
more widely respected in Africa, and if women exercised more political and socio-
economic power.  Human Rights Watch (HRW) and other organizations have
reported that domestic violence targeting women in some African countries has made
these women more vulnerable to HIV infection, in part by depriving them of the
power to negotiate condom use.9  For this reason, some policy advocates see a need
for greater support for fidelity campaigns primarily aimed at African men.  Women
also lack or have weak property rights in many African countries, making their
homes or property vulnerable to seizure by relatives when women suffer the loss of
their spouses due to AIDS.
Social and Economic Consequences
AIDS is having severe negative social and economic consequences in Africa,
and these effects are expected to continue for many years, as suggested by a January
2000 Central Intelligence Agency National Intelligence Estimate on the infectious
disease threats:
At least some of the hardest-hit countries, initially in Africa and later in other
regions, will face a demographic catastrophe as HIV/AIDS and associated
diseases reduce human life expectancy dramatically and kill up to a quarter of
their populations over the period of this Estimate. This will further impoverish
the poor, and often the middle class, and produce a huge and impoverished
orphan cohort unable to cope and vulnerable to exploitation and radicalization
(CIA, The Global Infectious Disease Threat and Its Implications for the United
States, [http://www.cia.gov/]).
The estimate predicted that AIDS would generate increased political instability and
slow democratic development.  The World Bank (Intensifying Action Against
HIV/AIDS in Africa, September 1999 ) has reached similar conclusions with respect
to Africa’s economic future:
The illness and impending death of up to 25% of all adults in some countries will
have an enormous impact on national productivity and earnings. Labor
productivity is likely to drop, the benefits of education will be lost, and resources
that would have been used for investments will be used for health care, orphan
care, and funerals. Savings rates will decline, and the loss of human capital will
affect production and the quality of life for years to come.
In the most severely affected countries, sharp drops in life expectancy are
occurring, reversing major gains achieved in recent decades.  According to UNAIDS,
average life expectancy in Africa is now 47 years due to AIDS, whereas it would
have been 62 years in its absence.  A March 2004 U.S. Census Bureau report
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ARC/04/INF/8, March 2004.
11 See [http://www.fao.org/hivaids].
predicted absolute population declines by 2010 in South Africa, Botswana, and three
other African countries due to AIDS. 
Rural Livelihoods.  Studies show that AIDS has devastating effects on rural
families. The father is often the first to fall ill, and when this occurs, farm tools and
animals may be sold to pay for his care, frequently leading to rapid impoverishment
of often already poor families. Should the mother also become ill, children may be
forced to shoulder responsibility for the full time care of their parents, farmsteads,
and often of themselves, despite their frequently limited knowledge about how to
carry out farm and domestic work.  Many also become orphans.  In 2001, the U.N.
Food and Agriculture Organization reported that AIDS had killed about 7 million
agricultural workers in 25 hard-hit countries in Africa and would likely cause 16
million more to die by 2020.  In 10 of the most affected countries, labor force losses
of between 10% to 26% were forecast.  (FAO, HIV/AIDS, Food Security, and Rural
Livelihoods, 2001).  Some experts attribute serious food shortages in southern Africa
in 2002 and 2003 to AIDS-related production losses.10  In February 2003, in separate
testimony before the Senate Foreign Relations Committee and the House
International Relations Committee, World Food Program (WFP) Executive Director
James Morris said that AIDS was a central cause of the famine.  In June 2004, Morris
said that southern Africa was in a “death spiral” due to the effects of the AIDS
pandemic, including the loss of human capacity and the devastation of rural areas,
with resulting negative consequences for food security (WFP press release).  The
FAO supports many programs to alleviate the diverse threats that AIDS poses to
agricultural production and food security.11
Workforce Depletion.  AIDS is blamed, in part, for increasing shortages of
skilled workers and teachers in several countries and is claiming many African lives
at middle and upper levels of public and private sector management.  Although
unemployment is generally high in Africa, trained personnel are not readily replaced.
Dr. Peter Piot, UNAIDS Executive Director, told a June 2, 2005, special U.N.
General Assembly meeting on AIDS that by 2006, 11 African countries will have lost
10% of their workforce to the disease.  A May 2002 World Bank study, Education
and HIV/AIDS: A Window of Hope, reported that over 30% of teachers are HIV
positive in parts of Malawi and Uganda, 20% in Zambia, and 12% in South Africa.
Reports from diverse sources have since continued to mirror such findings.
Security.  AIDS may have serious security consequences for much of Africa,
since HIV infection rates in many militaries are reportedly high.  Domestic political
stability could also be threatened in African countries if the security forces become
unable to perform their duties due to AIDS.  Peacekeeping is also at risk, because
African soldiers are expected to play an important peacekeeping role in Africa in the
years ahead.  The infection rate in South Africa has been estimated at 23%, with
higher rates reported for units based in heavily infected KwaZulu-Natal province.
Some Southern African militaries, however, are pursuing efforts to treat and counter
an increase in AIDS infections (Chicago Tribune, March 2006).
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Responses to the AIDS Epidemic
Donor governments, non-governmental organizations (NGOs) working in
Africa, and African governments have responded to the AIDS epidemic primarily by
attempting to reduce the number of new HIV infections through prevention programs,
and to some degree, by trying to ameliorate the damage done by AIDS to families,
societies, and economies.  A third response, treatment of AIDS sufferers with
antiretroviral drugs (ARVs) that can result in long-term survival, is increasing rapidly
in some African contexts, as treatment and drug distribution efforts expand, but
ARVs remain inaccessible to the vast majority of those in need of them in Africa
(See below, “AIDS Treatment Issues”).
Anti-AIDS programs and projects typically provide information on how HIV is
spread and on how it can be avoided through the media, posters, lectures, and skits.
Some success has been claimed for these efforts in persuading youth to delay the age
of “sexual debut” and to remain faithful to a single partner.  The Bush Administration
advocates an expansion of prevention programs focusing on abstinence until
marriage and marital faithfulness as effective means of slowing the spread of HIV,
although some critics maintain that this may be unrealistic in social environments
characterized by poverty and lack of education.  Some also question whether such
approaches can benefit poor married women in Africa, who have little power to
refuse the sexual demands of their husbands, whether infected or not — or, in some
cases, to control their extra-marital activities.  They are also often unable to refuse
spousal decisions to take more than one wife, given that polygamous marriage is
common and deeply embedded in many African societies. In January 2006, First
Lady Laura Bush defended abstinence approaches, saying that she had “always been
a little bit irritated by criticism of abstinence, because abstinence is absolutely, 100
percent effective in fighting a sexually transmittable disease.” She added that “In
many countries where girls feel obligated to comply with the wishes of men, girls
need to know that abstinence is a choice.”12 
Donor-sponsored voluntary counseling and testing (VCT) programs, where
available, enable African men and women to learn their HIV status.  In Botswana,
HIV tests are now offered as a routine part of medical visits, and many experts are
urging that this be done continent-wide.  AIDS awareness programs are found in
many African schools and, increasingly, in the workplace, where employers are
recognizing their interest in reducing infection rates among their employees.  Many
projects seek to make condoms readily available and to provide instruction in
condom use.  Several projects have had success in reducing mother-to-child
transmission by administering the anti-HIV drug AZT or nevirapine, before and
during birth, and during infant nursing. Nevirapine, however, has been the subject of
controversy.  In December 2004, the Associated Press reported that important
reporting flaws, including non-disclosure of bad drug reactions, had been found in
a study of nevirapine conducted in Uganda under U.S. National Institutes of Health
(NIH) sponsorship.  The allegations sparked criticism in Africa, including from the
South Africa’s ruling Africa National Congress, which in December 2004 charged
that top U.S. officials had “entered into a conspiracy with a pharmaceutical company
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sub-Saharan Africa and Least Developed Countries,” Jan. 12, 2006.
14 For further information, see CRS Report RL31712, The Global Fund to Fight AIDS,
Tuberculosis, and Malaria: Background and Current Issues, by Tiaji Salaam-Blyther.
to tell lies and promote the sales of nevirapine in Africa...” In response, NIH asserted
in a statement that “single-dose nevirapine is a safe and effective drug for preventing
mother to infant transmission of HIV.”  It termed as “absolutely false” any
implication of thousands of adverse reactions in the Uganda study. AIDS activists
and others worried that the controversy would discourage use of the drug, often the
only available means of preventing mother to child transmission (MTCT) of HIV.
A later National Academies’ Institute of Medicine assessment found that the Uganda
study was valid and that nevirapine should continue to be used for MTCT.
Church groups and humanitarian organizations have helped Africa deal with the
consequences of AIDS by setting up care and education programs for orphans.
Public-private partnerships have also become an important vehicle for responding to
the African AIDS pandemic.  The Bill and Melinda Gates Foundation has been a
major supporter of AIDS vaccine research and diverse AIDS programs pursued in
cooperation with African governments and donors.  The Rockefeller Foundation,
working with UNAIDS and others, has sponsored programs to improve AIDS care
in Africa, and both Bristol-Myers Squibb and Merck and Company, together with the
Gates Foundation and the Harvard AIDS Institute, have undertaken programs with
the Botswana government aimed at improving the country’s health infrastructure and
providing AIDS treatment to all who need it.  In Uganda, Pfizer and the Pfizer
Foundation fund Uganda’s AIDS Support Organization and the Infectious Diseases
Institute.  It has trained 250 AIDS specialists annually, many slated to work in rural
areas.  In January 2006, the Swiss drug firm Roche said it plans to help African firms
produce generic versions of its World Health Organization (WHO)-endorsed ARV,
Saquinavir, under its Technology Transfer Initiative.13
The Global Fund to Fight AIDS, Tuberculosis, and Malaria, created in January
2002, commits about 60% of its grant funds to Africa, and about 60% of its grants
worldwide go toward fighting AIDS.14  Despite these responses, UNAIDS maintains
that significant AIDS funding gaps remain.  According to a recent study, $14.9
billion will be needed in 2006 to fight HIV/AIDS in low- and middle-income
countries globally in 2006, whereas $8.9 billion is likely to be provided.  The funding
gap is projected to rise in future years, according to a June 2005 UNAIDS report. 
Leadership Reaction in South Africa and Elsewhere
Many observers believe that the spread of AIDS in Africa could have been
slowed if African leaders had been more engaged and outspoken at earlier stages of
the epidemic.  President Thabo Mbeki of South Africa has come in for particular
criticism on this score.  In April 2000, he wrote to then-President Clinton and other
heads of state defending dissident scientists who maintain that AIDS is not caused
by the HIV virus. In March 2001, Mbeki rejected appeals that the national assembly
declare the AIDS pandemic a national emergency.  Under mounting domestic and
international pressure, the South African government seemed to modify its position
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significantly when the government announced after an April 2002 cabinet meeting
that it would triple the national AIDS budget.  When an ARV drug treatment program
had not been launched by March 2003, however, the South African Treatment Action
Campaign (TAC) launched a civil disobedience campaign.  In August 2003, the
South African cabinet instructed the health ministry to develop a plan to provide
antiretroviral therapy nationwide, but by March 2004, TAC was threatening a lawsuit
unless the program was actually begun.  Finally, in April 2004, the government began
offering treatment at five hospitals in populous, highly urban Gauteng province.  In
its 2006 National Budget Review, the government reported that 112,000 patients
were “enrolled” for ARV therapy by December 2005 but did not specify the number
in publicly funded programs.  Estimates of total numbers in treatment and
proportions under public and private care vary widely. In February 2005, TAC
estimated that about 38% of 70,000 patients under ARV therapy were in public
programs; the remainder were receiving private care. Another activist group, the
International Treatment Preparedness Coalition, reported in November 2005 that of
150,000 persons receiving treatment in August 2005, 50%-53% were in public
programs.  In May 2006, UNAIDS reported that about 190,000 South Africans were
receiving ARV treatment, but that nearly 1 million, or more than 80% of those in
need of ARV therapy, were not yet receiving it in 2005. 
The delays in South Africa’s response to the pandemic have been costly, many
experts believe.  South African Health Department data have shown HIV infection
rates continuing to rise, though according to UNAIDS figures, rates were similar
between 2003 and 2005, though they rose among pregnant women. About 29.5% of
pregnant women in South Africa were found to be HIV positive in 2004, up from
27.9% in 2003 and 26.5% in 2002.  The Health Department estimates that there were
5.6 million HIV-positive South Africans in 2004. A September 2004 report by the
Bureau of Market Research at the University of South Africa predicted that AIDS-
related deaths would exceed 500,000 yearly from 2007 to 2011.  A lower rate of
growth in infections may reportedly be under way; a November 2005 South African
Human Sciences Research Council data release stated that South Africa’s AIDS
epidemic may be “leveling off.”  Some critics of the government have accused
government leaders of being “AIDS denialists” and of curtailing the rate of scaling
up access to ARVs because of some officials’ reported doubts about ARV use.  South
Africa’s Health Minister Manto Tshabalala Msimang has repeatedly questioned the
effectiveness of ARV drugs and has asserted that healthy diets and special foods,
such as raw garlic and lemon peel, can offer protection from the disease (Mail and
Guardian Online, May 5, 2005).  Former President Nelson Mandela, seeking to
combat the stigma associated with AIDS, announced in January 2005, that his son,
Makgatho, had died of AIDS.
In the rest of Africa, many heads of state, including the presidents of Uganda,
Botswana, Nigeria, and several other countries, are taking major roles in fighting the
epidemic.  Several regional AIDS initiatives have been launched. For example, in
August 2003, the Southern African Development Community (SADC) agreed to an
AIDS strategic framework, including the creation of a regional fund to fight the
disease.  The New Partnership for Africa’s Development (NEPAD), in partnership
with the African Union, UNAIDS, and other multinational entities, has formulated
a range of strategies for countering AIDS, though the products of these efforts appear
to be limited at present.
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Uganda’s president, Yoweri Museveni, has long been recognized for leading a
successful prevention campaign against AIDS in Uganda, where the ABC
(Abstinence, Be Faithful, or Use Condoms) transmission prevention program has
won wide praise.  A Senate Foreign Relations Africa Subcommittee hearing in May
2003, focused on “Fighting AIDS in Uganda: What Went Right.” Dr. Anne Peterson,
Assistant Administrator for Global Health at the U.S. Agency for International
Development (USAID), testified that the “Uganda success story is about prevention.”
She said that successes had been recorded in promoting abstinence and faithfulness
to partners, while increased condom use in recent years had also contributed to
prevalence declines.  Sophia Mukasa Monico, a member of the Global Health
Council and a former AIDS worker in Uganda, testified that all three program
elements are necessary for prevention to work but noted that the Ugandan epidemic
was still “raging”and that much work to counter it remained to be done. 
In February 2005, Johns Hopkins and Columbia University researchers released
a study of Rakai District, Uganda reporting that a local HIV prevalence decline was
due to condom use and the deaths of infected people.15  Abstinence and monogamy
appeared not to be increasing. Some saw this as evidence that sexual behavior change
programs were less important than expected.  Others argued that behavior had likely
changed substantially prior to the study. In July 2005, First Lady Laura Bush,
speaking in South Africa during a trip to Africa that included visits with AIDS
patients and orphans, said that the Uganda-developed ABC model was “successful”
and added that “ABC stands for Abstinence, Be faithful, and correct and consistent
use of Condoms.”  Conflicting reports appeared in late summer 2005 regarding a
shortage of condoms in Uganda for preventing HIV.  Some AIDS activists and others
blamed the alleged shortage on an emphasis on abstinence in U.S.-funded AIDS
prevention programs and a change in policy by Ugandan government officials, who
denied a shortage existed.  A U.S. official attributed the problem to a shipment of
defective condoms.
AIDS Antiretroviral Treatment Issues
Access by the poor to antiretroviral drugs (ARVs) has been perhaps the most
contentious issue surrounding the response to Africa’s AIDS epidemic. ARVs are
used in a treatment regime generally dubbed Antiretroviral Therapy (ART).  Three
or more ARVs are often used in combination to halt the genetic replication of the
HIV virus at different stages in its life cycle, a treatment regime known as Highly
Active ART (HAART).  ART can enable AIDS victims to live relatively normal lives
and permit long-term survival rather than early death. ARVs have proven highly
effective in developed countries, including the United States, where AIDS, the
eighth-ranked cause of death in 1996, was no longer among the top 15 causes by
1998, according to the U.S. Health and Human Services Department.
The high cost of ARVs has proved a key obstacle to large scaling-up of access
to ART in Africa, where most patients are poor and lack health insurance.  Once
estimated at between $10,000 and $15,000 per person per year, ART costs have
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dropped dramatically in recent years. In May 2000, five major pharmaceutical
companies agreed to negotiate sharp reductions in the price of AIDS drugs sold in
Africa.  UNAIDS launched a program in cooperation with pharmaceutical firms to
boost treatment access. In June 2001, it reported that 10 African countries had
reached agreement with drug makers that would significantly reduce prices in
exchange for health infrastructure improvements to assure that ARVs are
administered safely.  Initiatives to expand ARV availability continued, and treatment
became a major focus of Global Fund and the President’s Emergency Plan for AIDS
Relief (PEPFAR) programs (see below.  In December 2003, the WHO formally
launched its “3 by 5” campaign to treat 3 million AIDS patients in poor countries by
2005, with resources from the Global Fund and donors.  Leaders of the G8,
concluding their summit in Scotland in July 2005, promised “a package for HIV
prevention, treatment, and care,” with the goal of providing “universal access to
treatment for all those who need it by 2010.”
In October 2003, former President Bill Clinton announced that his Clinton
Foundation HIV/AIDS Initiative (CHAI) had organized a program to provide generic
three-drug ARV treatment in Africa and the Caribbean for about $.38 per day per
AIDS patient using drugs manufactured in India and South Africa with backing from
private donors and some donor governments, among other sources.  In April 2004,
the Clinton Foundation announced an agreement with UNICEF, the World Bank, and
the Global Fund to expand the program to more than 100 developing countries.  In
April 2005, CHAI announced a pediatric AIDS program intended to put 10,000 HIV-
positive children on ARV therapy in at least 10 countries in 2005, doubling the
number of children in treatment.  On January 12, 2006, former President Bill Clinton
announced that CHAI had negotiated new agreements to lower prices of
WHO-evaluated HIV tests by 50% and those of two antiretroviral drugs by 30%.
These will be made available to the CHAI Procurement Consortium, a group of
countries eligible to make purchases under CHAI agreements.  It includes 50
developing countries.  CHAI also helps countries to implement large-scale, integrated
care, treatment, and prevention programs.  Partner governments take the lead; CHAI
provides technical aid, mobilizes human and financial resources, and promotes
sharing of best practices. 
 As a result of ARV scaling up efforts, UNAIDS reported in May 2006 an
estimated 810,000 or about 17% of a total of about 4.7 million Africans in need of
ART (72% of those in need worldwide) were receiving it by late 2005.16  This
number was up from about 500,000 in June 2005 and up from about 150,000 a year
earlier.17  Despite such successes, UNAIDS and WHO had reported in December
2005 that progress in expanding treatment and care in Africa was uneven across the
region and within countries.  In general, according to a report by UNAIDS in
December 2005, there was “extensive unmet need” in most of Africa.  By late 2005,
UNAIDS reported, RT coverage levels of  45% or greater had been achieved in
countries such as Botswana, Senegal, and Uganda, Namibia.  In slightly under a third
of African countries, coverage rates ranged between 10% and 31%, while  in 18
countries, rates were below 10%.  About 23.5% of all those receiving ART resided
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in South Africa.18  ART access in rural areas, where the majority of the population
in many African countries — and the bulk of AIDS patients — live, is generally
much poorer than in urban areas.
Whether African countries are ready to “absorb” (effectively use) sharp
increases in treatment funding has been another issue.  AIDS activists believe that
millions of Africans could quickly be given access to AIDS drugs.  Others maintain
that African supply channels cannot make the drugs consistently available to millions
of patients and that regular monitoring of patients by medical personnel is not
possible in much of Africa.  Monitoring is necessary, they maintain, to deal with side
effects and to adjust medications if drug resistance emerges.  Many fear that if the
drugs are taken irregularly, resistant HIV strains will emerge that could cause
untreatable infections globally, although many African patients reportedly follow
their AIDS therapy regimens equally or more consistently than many American
patients.  The creation of once-daily combined ARV tablets is widely seen as a likely
way to facilitate access to and adherence to ARV therapy, notably in impoverished
settings.  In January 2006, the multinational drug firms Gilead and Bristol-Myers
Squibb announced that they had jointly developed such a tablet for certain drugs.  For
some, the correct response to weaknesses in Africa’s basic health care systems is to
devote resources to strengthening those systems.  News reports indicate that scaling
up of treatment is often stymied by African government administrative inefficiencies
and by donor limitations on what their funds may be used to purchase. 
Botswana’s President Festus Mogae told a November 2003 meeting, held in
Washington by the Center for Strategic and International Studies, that the widely-
praised treatment program in his country is being hampered by a “brain drain” of
health personnel.  African physicians, nurses, and technicians are often hired by
foreign governments, international organizations, and non-governmental
organizations outside of Africa, or migrate to developed countries to take advantage
of generally better job opportunities in such countries.  The health minister of
Mozambique, which has launched a pilot ARV drug treatment program, said in May
2004 that the country was unable to launch a nationwide program because of serious
shortages of staff and equipment.  WHO and other organizations have reported that
Africa has the lowest ratio of health workers to population of any region.  WHO
reported that in 2005, thee were 2.3 health workers (of all kinds) per 1,000 persons
on average across Africa.  It also reported that 36 of 46 (78%) African countries
surveyed had critical shortages of doctors, nurses and midwives, and would have to
increase such professionals by 139% in order to adequately meet current needs.19
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AIDS activists have urged that African governments issue “compulsory
licenses” to allow the manufacture or importation of inexpensive copies of patented
AIDS drugs (“generic drugs”).  In November 2001, a ministerial-level meeting of the
World Trade Organization(WTO) in Doha, Qatar, approved a declaration stating that
the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
should be implemented in a manner supportive of promoting access to medicines for
all.  The declaration affirmed the right of countries to issue compulsory licenses and
gave the least-developed countries until 2016 to implement TRIPS.  The question of
whether countries manufacturing generic drugs, such as India or Thailand, should be
permitted to export to poor countries was left for further negotiation through a
committee known as the Council for TRIPS. 
Although the Doha declaration drew broad praise, some AIDS activists
criticized it for not permitting imports of generics.  Some in the pharmaceutical
industry, on the other hand, expressed concern that the declaration was too
permissive and might reduce profits that, they argued, fund medical research.  Others,
however, maintained that the declaration would have little practical impact; in their
view, poverty, rather than patents, is the key obstacle to drug access in Africa.20  In
August 2003, the WTO reached agreement on a plan to allow poor countries to
import generic copies of essential drugs, but the debate over access to ARVs in
Africa seems likely to continue.  This agreement was ratified in December 2005 at
the Hong Kong WTO ministerial meeting.  In March 2005, India’s parliament passed
patent legislation expected to sharply raise prices in Africa and elsewhere for Indian-
manufactured generic copies of newly discovered AIDS medications.  Cheap generic
copies of existing drugs can still be sold, although sellers will have to pay licensing
fees to patent holders.
Effectiveness of the Response
The response to AIDS in Africa has had some successes, most notably in
Uganda, where the rate of infection among pregnant women in urban areas fell from
29.5% in 1992 to 5% in 2001 (UNAIDS, AIDS Epidemic Update, December 2002).21
In most African countries, prevalence rates in 2005 were roughly similar to those in
2003, with only marginal increases or decreases.  UNAIDS findings have indicated
that sexual behavior patterns among young urbanites in some other countries may be
changing in ways that combat the spread of HIV, although increases among
populations continue in many African cities.  Despite some success stories, however,
the number of infected people in Africa continues to grow, in part due to general
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population increases.  The absolute number of HIV-positive persons in Africa
increased from 21.6 million in 2003 to 22.4 million in late 2005.
Experts contend that there are multiple social barriers to a more effective AIDS
response in Africa, such as cultural norms that make it difficult for many
government, religious, and community leaders to acknowledge or discuss sexual
matters, including sex practices, prostitution, and the use of condoms.  However,
experts continue to advocate AIDS awareness and public education and outreach
efforts as essential components of the response to the epidemic.  Indeed, there is
strong support for an intensification of such efforts, as well as adaptations to make
them more effective.
The lives of HIV patients could be significantly prolonged and improved, some
maintain, if more were done to identify and treat the opportunistic infections, notably
tuberculosis (TB), that often accompany AIDS. Millions of Africans suffer dual HIV-
TB infections, and their combined effects dramatically shorten life.  TB can be cured
by multi-month, combined drug treatments, even in HIV-infected patients. However,
according to the WHO, Africans often delay seeking treatment for TB or do not
complete their drug regimens, contributing to high death rates among those with dual
infections.  UNAIDS and the WHO have recommended that Africans infected with
HIV be treated with an antibiotic/sulfa drug combination known as cotrimoxazole in
order to prevent opportunistic infections. Studies indicate that the drug could reduce
AIDS death rates at a cost of between $8 and $17 per year per patient.  The Pfizer
Corporation donates the anti-fungal Diflucan (fluconazole), used to treat AIDS-
related opportunistic infections (such as cryptococcal meningitis, a dangerous brain
inflammation) to patients in 18 African countries through the Pfizer Diflucan
Partnership Program (DPP). DPP is a public-private effort in collaboration with
health ministries, local clinics, and non-governmental organizations.  In partnership
with the International Association for Physicians in AIDS Care, Pfizer also supports
education and training for health care providers of diagnosis and management for
opportunistic infection.
Further information on the response to AIDS in Africa and elsewhere may be
found at the following websites.
 — Centers for Disease Control (CDC): [http://www.cdc.gov/nchstp/od/nchstp.html]
 — Global Fund to Fight AIDS, Tuberculosis & Malaria: [http://www.theglobalfund.
org/en]
 — International AIDS Vaccine Initiative: [http://www.iavi.org]
 — International Association of Physicians in AIDS Care: [http://www.iapac.org]
 — Kaiser Network: [http://www.kaisernetwork.org]; click “HIV Daily Reports”
 — UNAIDS: [http://www.unaids.org/en/default.asp]
 — USAID: [http://www.usaid.gov/our_work/global_health/aids/index.html]
 — World Bank: [http://www.worldbank.org]; click “Topics >> AIDS”
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U.S. Policy
U.S. concern over AIDS in Africa began to mount during the 1980s, as the
severity of the epidemic became apparent. In 1987, Congress earmarked FY1988
funds for fighting AIDS worldwide, and House appropriators noted that in Africa,
AIDS had the potential for “undermining all development efforts” to date (H.Rept.
100-283).  In subsequent years, Congress supported AIDS spending at or above
levels requested by the executive branch, either through earmarks or report language.
Nevertheless, a widely discussed July 2000 Washington Post article called into
question the adequacy and timeliness of the early U.S. response to the HIV/AIDS
threat in Africa (Barton Gellman, “The Global Response to AIDS in Africa: World
Shunned Signs of Coming Plague,” Washington Post, July 5, 2000). 
Clinton Administration
As the severity of the epidemic continued to deepen, many of those concerned
for Africa’s future, both inside and outside government, came to feel that more
should be done.  In July 1999, the Clinton Administration proposed $100 million in
additional spending for a global LIFE (Leadership and Investment in Fighting an
Epidemic) AIDS initiative, with a heavy focus on Africa.22  Funds approved during
the FY2000 appropriations process supported most of this initiative, and funded the
engagement of the Department of Health and Human Services (HHS), the
Departments of Labor (DoL), and the Department of Defense (DoD), in addition to
USAID, in the global fight against HIV/AIDS.  On June 27, 2000, the Peace Corps
announced that all volunteers serving in Africa would be trained as AIDS educators.
USAID asserted in 2001 that its support of multilateral efforts and direct sponsorship
of regional and bilateral programs had made it the global leader in the international
response to AIDS since 1986, when it initiated AIDS prevention programs in
developing countries (USAID, Leading the Way: USAID Responds to HIV/AIDS,
September 2001).  USAID had sponsored AIDS education programs; trained AIDS
educators, counselors, and clinicians; supported condom distribution; and sponsored
AIDS research.  USAID claimed several successes in Africa.  These included helping
to reduce HIV prevalence among young Ugandans; preventing an outbreak of the
epidemic in Senegal; reducing the frequency of sexually transmitted infections in
several African countries; sharply increasing condom availability in Kenya and
elsewhere; assisting children orphaned by AIDS; and sponsoring the development of
useful new technologies, including the female condom.
Bush Administration
Combating the AIDS pandemic in Africa has been an important Bush
Administration foreign assistance program goal.  In May 2001, President Bush made
the “founding pledge” of $200 million to the Global Fund, and in June 2002, he
announced a $500 million International Mother and Child HIV Prevention Initiative
to support efforts to prevent mother-to-child AIDS transmission.  Eight African
CRS-17
23 These reports are published online. See [http://www.state.gov/s/gac/progress].
countries were named as beneficiaries.  In his January 2003 State of the Union
address, President Bush announced the launching of the President’s Emergency Plan
for AIDS Relief (PEPFAR), pledging $15 billion for fiscal years 2004 through 2008,
including $10 billion in “new money,” that is, spending in addition to then current
levels. In July 2003, President Bush made AIDS a special focus during a five-day trip
to Africa.  On July 8, in Senegal, the President told Africans, “we will join with you
in turning the tide against AIDS in Africa.”  On July 10, speaking in Botswana, the
President said that, “this is the deadliest enemy Africa has ever faced, and you will
not face this epidemic alone.”  In September 2003, then Secretary of State Colin
Powell told a U.N. General Assembly special session on AIDS that the epidemic was
“more devastating than any terrorist attack” and that the United States would “remain
at the forefront” of efforts to combat the epidemic.
PEPFAR was authorized by P.L. 108-25, the United States Leadership Against
Global HIV/AIDS, Tuberculosis, and Malaria Act of 2003, signed into law by
President Bush on May 27, 2003.  Its implementation has resulted in major spending
increases for HIV/AIDS prevention, care, and treatment in 15 “focus countries,” 12
in Africa (Botswana, Cote d’Ivoire, Ethiopia, Kenya, Mozambique, Namibia,
Nigeria, Rwanda, South Africa, Tanzania, Uganda, and Zambia).  PEPFAR funds are
provided through the Global HIV/AIDS Initiative (GHAI), headquartered at the State
Department.  The GHAI is headed by a U.S. Global AIDS Coordinator, who
coordinates GHAI programs in focus countries and other international AIDS
programs implemented by USAID and other agencies.  Permanent incumbents in the
Global AIDS Coordinator position are nominated by the president and confirmed by
the Senate.  The first Global AIDS Coordinator was Randall Tobias, who is now
Administrator of USAID and the Director of U.S. Foreign Assistance. Dr. Mark
Dybul is the Acting U.S. Global AIDS Coordinator.
In February 2004, the State Department issued a report [http://www.state.gov/s/
gac/rl/or/c11652.htm] which provided details on how PEPFAR would be
implemented, and proposed to use initial PEPFAR funds to support several
“public-private partnership” treatment programs.  PEPFAR aims to prevent 7 million
new infections globally, provide ARV drugs for 2 million infected people, and
provide care for 10 million infected people, including orphans.  The Administration
has submitted to Congress two subsequent annual PEPFAR reports that describe the
status of PEPFAR program policy and program administration, as well as a number
of other related  reports.23
Many AIDS activists and others have praised the President’s initiatives. During
the initial stages of its implementation, however, some critics maintained that
PEPFAR was starting too slowly. Some have also characterized the program as too
strongly unilateral and would like the United States to act in closer cooperation with
other countries and donors, especially the Global Fund.  Some have questioned
whether PEPFAR will do enough to directly strengthen African health care
institutions and capabilities for coping with AIDS over the long term, or whether the
funds will go primarily to U.S.-based organizations.  Some also urged increased
appropriations, as some have continued to do.  U.N. Secretary General Kofi Annan,
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during an interview at the July 2004 international AIDS conference in Bangkok,
urged U.S. contributions of $1 billion annually for the Global Fund.  Then-U.S.
Global AIDS Coordinator Randall Tobias responded by stating that “It’s not going
to happen.”24  Annan asked the United States to show the same leadership in the
AIDS struggle that it had shown in the war on terrorism. U.S. State Department
spokesman Richard Boucher rejected the implied criticism, saying that the Bush
Administration had taken the AIDS crisis very seriously and that the $15 billion
pledged to fight the epidemic over five years was an “enormous and significant
amount.”  More recently, some healthcare advocates have criticized what they see as
a programmatic over-emphasis on efforts to promote the use of abstinence in the
prevention of HIV, as opposed to the distribution and promotion of condoms for this
purpose.  Critics have charged that funding for PEPFAR abstinence programs,
notably in Africa, has increasingly replaced other HIV prevention measures and that
the United States is today sending fewer condoms abroad than in 1990 (Center for
Health and Gender Equity, Prevention Funding Under [PEPFAR]: Law, Policy and
Interpretation, December 2005).  Some have cited as evidence for this contention,
an April 2006 Government Accountability Office (GAO) report entitled Global
Health: Spending Requirement Presents Challenges for Allocating Prevention
Funding under the President’s Emergency Plan for AIDS Relief.25  The GAO found
that guidance requiring that 33% of PEPFAR HIV prevention funds be spent on
abstinence and faithfulness-focused programs had, in some cases, led to decreases in
funding for certain other types of HIV prevention efforts.  It also suggested that the
guidance contained ambiguities that had created uncertainties among some country
field teams about how to implement PEPFAR programs.
In March 2005, the Department of State released Engendering Bold Leadership:
The President’s Emergency Plan for AIDS Relief, the first annual report to Congress
on the initiative. In an introductory letter to the report, Randall Tobias called
PEPFAR “coordinated, accountable, and powerful.”  The report stated that 152,000
African patients were receiving AIDS treatment due to PEPFAR and that 119 million
had been reached with mass media campaigns promoting abstinence and faithfulness,
while 71 million had been reached with messages promoting other prevention
measures, including the use of condoms.  The President’s second annual  report to
Congress stated that while 115.23 million condoms had been shipped to Focus
Countries in 2001, 198.4 million had been shipped in 2005 — a 72% increase over
2001.
Other Potential U.S. Measures.  Senator Frist introduced S. 850 on April
19, 2005, that would authorize a Global Health Corps to send U.S. health volunteers
abroad and expand the availability of health personnel, items, and related services.
That same day, the National Academies’ Institute of Medicine (IOM) released a
report calling for a U.S. Global Health Service to mobilize health personnel to work
in the 15 PEPFAR focus countries.  An initial deployment of 150 key professionals
would be paid full salary; others would receive $35,000 fellowships and student loan
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repayments up to $25,000.  Some suggested that funds might better be spent training
and retaining indigenous health personnel, particularly in Africa; others noted that
training was a key part of the IOM proposal, which they praised as a dynamic
response to the AIDS crisis. 
Treatment. The Financial Times reported in April 2004 that the United States
was withholding support from a program intended to treat 140,000 AIDS patients in
Kenya with antiretrovirals because it would rely on a generic three-drug Fixed Dose
Combination (FDC) pill.  Many favor approval of FDCs, including copies of drugs
made by different companies, on grounds that they are simpler to prescribe and need
to be taken just once or twice a day. U.S. officials had expressed concerns that further
study was needed to assure that their widespread or improper distribution did not
contribute to the emergence of resistant HIV strains.  The issue was submitted to a
panel of experts instructed to report by mid-May 2004.  Several members of
Congress later wrote to President Bush asking that the United States join an
international consensus that generics are safe and essential for AIDS treatment.  In
May 2004, then-Health and Human Services Secretary Tommy Thompson announced
that the U.S. Food and Drug Administration (FDA) was instituting an expedited
process that could lead to the approval of the use of FDCs in PEPFAR-funded
programs.  Many hailed the news as a step forward in making cheaper and more
reliable antiretroviral therapy available in Africa, but critics said it placed an
unnecessary hurdle in the way of distributing such pills.  They maintained that the
United States should have relied on the approval process of the World Health
Organization, which had already cleared such pills. By June 2005, the FDA had
reportedly cleared seven generic antiretrovirals manufactured in South Africa and
India.  However, the Boston Globe reported on June 20 that four African countries,
Nigeria, Uganda, Ethiopia, and Tanzania, were refusing to accept generic FDA-
approved drugs for use in U.S.-funded treatment programs. Instead, the countries
sought approval of the drugs by WHO. 
Spending.  Table 2 reports available information on recent U.S. spending
levels on AIDS programs in Africa.  Under the FY2007 budget request, the 12
countries would receive a 61% boost in AIDS-related aid, to $1.99 billion, under the
State Department’s Global HIV/AIDS Initiative account.  The Office of the Global
AIDS Coordinator (OGAC) at the State Department administers the bulk of U.S.
AIDS assistance to Africa.  PEPFAR was enacted, in part, to simplify the
international AIDS budget, enhance transparency, and stress the President’s interest
in fighting AIDS and his backing for what the State Department reports is “the largest
commitment ever by a single nation for an international health initiative.”26  Prior to
PEPFAR, the principal channels for HIV/AIDS assistance to Africa were USAID and
the Global AIDS Program (GAP) of the Centers for Disease Control (CDC) in the
Health and Human Services Department.  Most USAID spending on AIDS in Africa
is through the Child Survival and Health Programs Fund.  Limited amounts are
provided through other accounts, such as multi-functional Economic Support Fund,
Peace Corps, and Migration and Refugee Assistance.  The Department of Defense
(DoD) has undertaken an HIV/AIDS Prevention Program, primarily with African
armed forces and administered by the Naval Health Research Center in San Diego.
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It also focuses on education and creation of policy responses.  As in other recent
years, the Administration did not request funding for the program in FY2007.  In
FY2006 Congress continued to support it by appropriating $5.5 million (of which
$3.2 million went to Africa).  Foreign Military Financing (FMF) funds are also used
to support this initiative. A Department of Labor (DOL) program in the past
supported AIDS education in the workplace in several African countries, but was not
funded in FY2006.  Funds for these DOL efforts were not requested in FY2007.27
Additional U.S. funds reach Africa indirectly through the AIDS programs of the
United Nations (U.N.), the World Bank, and the Global Fund.
The scale of the response to the pandemic in Africa by the United States and
other donors remains a subject of intense debate.  The U.N. Special Envoy for
HIV/AIDS in Africa, Stephen Lewis, has been a persistent critic, telling a September
2003 conference on AIDS in Africa that he was “enraged by the behavior of the rich
powers” with respect to the epidemic.  Many activist groups have made similar
critiques.  The singer Bono said he had a “good old row” with President Bush in a
September 2003 meeting on the level of U.S. funding for fighting the international
AIDS epidemic.  Nonetheless, as noted above, others have argued that Africa’s
ability to absorb increased AIDS funding is limited and that health infrastructure will
have to be expanded before new funds can be spent effectively.
Table 2.  U.S. Bilateral Spending on Fighting AIDS in Africa
($ millions)
FY2005 Actual FY2006 Estimate FY2007 Request
USAID 81.44 78.48 78.48
CDC (GAP) 63.90 69.17 69.17
State (GHAI) 885.66 1,238.65 1,994
DOD 4.1 3.2 -
FMF 1.98 1.98 1.60
Total 1,037.08 1,391.48 2,143.25
Legislative Action, 2000-2004
The Global AIDS and Tuberculosis Relief Act of 2000 (P.L. 106-264), enacted
in August 2000, authorized funding for FY2001 and FY2002 for a comprehensive,
coordinated, worldwide HIV/AIDS effort under USAID.  In the 107th Congress,
several bills were introduced with international or Africa-related AIDS-related
provisions.  A major international AIDS authorization bill, H.R. 2069, passed both
chambers during the 107th Congress but did not go to conference.28  In May 2003,
Congress approved and President Bush signed into law H.R. 1298/ P.L. 108-25, the
U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003. It
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authorized th establishment of PEPFAR and the allocation of $3 billion per year for
the program from FY2004 through FY2008 (a total of $15 billion), and created the
office of the Global AIDS Coordinator at the State Department.  Appropriations
measures have supported a variety of programs helping Africa fight the pandemic.29
Legislation in the 109th Congress
P.L. 109-95 (formerly H.R. 1409, Lee), the Assistance for Orphans and Other
Vulnerable Children in Developing Countries Act of 2005, was signed into law in
November 2005.  P.L. 109-102 (formerly H.R. 3057, Kolbe), the Foreign Operations,
Export Financing, and Related Programs Appropriations Act, 2006 and P.L. 109-149
(formerly H.R. 3010, Regula, the Departments of Labor, Health and Human Services,
and Education, and Related Agencies Appropriations Act, 2006, provided the bulk
of U.S. international AIDS funding in FY2006.  Bills introduced in the 109th
Congress, with provisions related to the African AIDS pandemic, include the
following: H.R. 155 (Millender-McDonald), Mother to Child Plus Appropriations
Act for Fiscal Year 2005; H.R. 164 (Millender McDonald), International Pediatric
HIV/AIDS Network Act of 2005; H.R. 2601 (Smith), Foreign Relations
Authorization Act, Fiscal Years 2006 and 2007; S. 600 (Lugar), Foreign Affairs
Authorization Act, Fiscal Years 2006 and 2007; S. 850 (Frist), Global Health Corps
Act of 2005; and S. 2125 (Obama), Democratic Republic of the Congo Relief,
Security, and Democracy Promotion Act of 2005.
